Report cover image

Non-benzodiazepine Hypnotics Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 146 Pages
SKU # APRC20352380

Description

Summary

According to APO Research, the global Non-benzodiazepine Hypnotics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Non-benzodiazepine Hypnotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Non-benzodiazepine Hypnotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Non-benzodiazepine Hypnotics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Non-benzodiazepine Hypnotics include Abbott, Tianjin Tasly Saint Pharmaceuticals, Sun Pharmaceutical, Shanghai Pharmaceuticals, Qilu Pharmaceutical, Kanghong Pharmaceuticals, Changzhou Siyao Pharmaceutical, Wockhardt and Torrent Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-benzodiazepine Hypnotics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-benzodiazepine Hypnotics.

The report will help the Non-benzodiazepine Hypnotics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Non-benzodiazepine Hypnotics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-benzodiazepine Hypnotics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Non-benzodiazepine Hypnotics Segment by Company

Abbott
Tianjin Tasly Saint Pharmaceuticals
Sun Pharmaceutical
Shanghai Pharmaceuticals
Qilu Pharmaceutical
Kanghong Pharmaceuticals
Changzhou Siyao Pharmaceutical
Wockhardt
Torrent Pharma
Teva Pharmaceuticals
Tapi Teva
Sanofi-aventis
Northstar Rx
Mylan Pharmaceuticals
Kanghong Pharmaceutical
Hikma Pharmaceuticals
Glenmark Life Sciences
Endo
Dr. Reddy’s Laboratories
Centaur Pharmaceuticals
Apotex
Admiron Life
Non-benzodiazepine Hypnotics Segment by Type

Zaleplon
Zopiclone
Zolpidem
Other
Non-benzodiazepine Hypnotics Segment by Application

Hospital
Clinic
Other
Non-benzodiazepine Hypnotics Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-benzodiazepine Hypnotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-benzodiazepine Hypnotics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-benzodiazepine Hypnotics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Non-benzodiazepine Hypnotics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Non-benzodiazepine Hypnotics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Non-benzodiazepine Hypnotics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

146 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Non-benzodiazepine Hypnotics Market Size (2020-2031)
2.2.2 Global Non-benzodiazepine Hypnotics Sales (2020-2031)
2.2.3 Global Non-benzodiazepine Hypnotics Market Average Price (2020-2031)
2.3 Non-benzodiazepine Hypnotics by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Zaleplon
2.3.3 Zopiclone
2.3.4 Zolpidem
2.3.5 Other
2.4 Non-benzodiazepine Hypnotics by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Clinic
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Non-benzodiazepine Hypnotics Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Non-benzodiazepine Hypnotics Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Non-benzodiazepine Hypnotics Revenue of Manufacturers (2020-2025)
3.4 Global Non-benzodiazepine Hypnotics Average Price by Manufacturers (2020-2025)
3.5 Global Non-benzodiazepine Hypnotics Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Non-benzodiazepine Hypnotics, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Non-benzodiazepine Hypnotics, Product Type & Application
3.8 Global Manufacturers of Non-benzodiazepine Hypnotics, Established Date
3.9 Global Non-benzodiazepine Hypnotics Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Abbott
4.1.1 Abbott Company Information
4.1.2 Abbott Business Overview
4.1.3 Abbott Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Abbott Non-benzodiazepine Hypnotics Product Portfolio
4.1.5 Abbott Recent Developments
4.2 Tianjin Tasly Saint Pharmaceuticals
4.2.1 Tianjin Tasly Saint Pharmaceuticals Company Information
4.2.2 Tianjin Tasly Saint Pharmaceuticals Business Overview
4.2.3 Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.2.5 Tianjin Tasly Saint Pharmaceuticals Recent Developments
4.3 Sun Pharmaceutical
4.3.1 Sun Pharmaceutical Company Information
4.3.2 Sun Pharmaceutical Business Overview
4.3.3 Sun Pharmaceutical Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Sun Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
4.3.5 Sun Pharmaceutical Recent Developments
4.4 Shanghai Pharmaceuticals
4.4.1 Shanghai Pharmaceuticals Company Information
4.4.2 Shanghai Pharmaceuticals Business Overview
4.4.3 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.4.5 Shanghai Pharmaceuticals Recent Developments
4.5 Qilu Pharmaceutical
4.5.1 Qilu Pharmaceutical Company Information
4.5.2 Qilu Pharmaceutical Business Overview
4.5.3 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
4.5.5 Qilu Pharmaceutical Recent Developments
4.6 Kanghong Pharmaceuticals
4.6.1 Kanghong Pharmaceuticals Company Information
4.6.2 Kanghong Pharmaceuticals Business Overview
4.6.3 Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.6.5 Kanghong Pharmaceuticals Recent Developments
4.7 Changzhou Siyao Pharmaceutical
4.7.1 Changzhou Siyao Pharmaceutical Company Information
4.7.2 Changzhou Siyao Pharmaceutical Business Overview
4.7.3 Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
4.7.5 Changzhou Siyao Pharmaceutical Recent Developments
4.8 Wockhardt
4.8.1 Wockhardt Company Information
4.8.2 Wockhardt Business Overview
4.8.3 Wockhardt Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Wockhardt Non-benzodiazepine Hypnotics Product Portfolio
4.8.5 Wockhardt Recent Developments
4.9 Torrent Pharma
4.9.1 Torrent Pharma Company Information
4.9.2 Torrent Pharma Business Overview
4.9.3 Torrent Pharma Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Torrent Pharma Non-benzodiazepine Hypnotics Product Portfolio
4.9.5 Torrent Pharma Recent Developments
4.10 Teva Pharmaceuticals
4.10.1 Teva Pharmaceuticals Company Information
4.10.2 Teva Pharmaceuticals Business Overview
4.10.3 Teva Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Teva Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.10.5 Teva Pharmaceuticals Recent Developments
4.11 Tapi Teva
4.11.1 Tapi Teva Company Information
4.11.2 Tapi Teva Business Overview
4.11.3 Tapi Teva Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Tapi Teva Non-benzodiazepine Hypnotics Product Portfolio
4.11.5 Tapi Teva Recent Developments
4.12 Sanofi-aventis
4.12.1 Sanofi-aventis Company Information
4.12.2 Sanofi-aventis Business Overview
4.12.3 Sanofi-aventis Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Sanofi-aventis Non-benzodiazepine Hypnotics Product Portfolio
4.12.5 Sanofi-aventis Recent Developments
4.13 Northstar Rx
4.13.1 Northstar Rx Company Information
4.13.2 Northstar Rx Business Overview
4.13.3 Northstar Rx Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Northstar Rx Non-benzodiazepine Hypnotics Product Portfolio
4.13.5 Northstar Rx Recent Developments
4.14 Mylan Pharmaceuticals
4.14.1 Mylan Pharmaceuticals Company Information
4.14.2 Mylan Pharmaceuticals Business Overview
4.14.3 Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.14.4 Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.14.5 Mylan Pharmaceuticals Recent Developments
4.15 Kanghong Pharmaceutical
4.15.1 Kanghong Pharmaceutical Company Information
4.15.2 Kanghong Pharmaceutical Business Overview
4.15.3 Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
4.15.5 Kanghong Pharmaceutical Recent Developments
4.16 Hikma Pharmaceuticals
4.16.1 Hikma Pharmaceuticals Company Information
4.16.2 Hikma Pharmaceuticals Business Overview
4.16.3 Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.16.5 Hikma Pharmaceuticals Recent Developments
4.17 Glenmark Life Sciences
4.17.1 Glenmark Life Sciences Company Information
4.17.2 Glenmark Life Sciences Business Overview
4.17.3 Glenmark Life Sciences Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.17.4 Glenmark Life Sciences Non-benzodiazepine Hypnotics Product Portfolio
4.17.5 Glenmark Life Sciences Recent Developments
4.18 Endo
4.18.1 Endo Company Information
4.18.2 Endo Business Overview
4.18.3 Endo Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.18.4 Endo Non-benzodiazepine Hypnotics Product Portfolio
4.18.5 Endo Recent Developments
4.19 Dr. Reddy’s Laboratories
4.19.1 Dr. Reddy’s Laboratories Company Information
4.19.2 Dr. Reddy’s Laboratories Business Overview
4.19.3 Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.19.4 Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Product Portfolio
4.19.5 Dr. Reddy’s Laboratories Recent Developments
4.20 Centaur Pharmaceuticals
4.20.1 Centaur Pharmaceuticals Company Information
4.20.2 Centaur Pharmaceuticals Business Overview
4.20.3 Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.20.4 Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
4.20.5 Centaur Pharmaceuticals Recent Developments
4.21 Apotex
4.21.1 Apotex Company Information
4.21.2 Apotex Business Overview
4.21.3 Apotex Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.21.4 Apotex Non-benzodiazepine Hypnotics Product Portfolio
4.21.5 Apotex Recent Developments
4.22 Admiron Life
4.22.1 Admiron Life Company Information
4.22.2 Admiron Life Business Overview
4.22.3 Admiron Life Non-benzodiazepine Hypnotics Sales, Revenue and Gross Margin (2020-2025)
4.22.4 Admiron Life Non-benzodiazepine Hypnotics Product Portfolio
4.22.5 Admiron Life Recent Developments
5 Global Non-benzodiazepine Hypnotics Market Scenario by Region
5.1 Global Non-benzodiazepine Hypnotics Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Non-benzodiazepine Hypnotics Sales by Region: 2020-2031
5.2.1 Global Non-benzodiazepine Hypnotics Sales by Region: 2020-2025
5.2.2 Global Non-benzodiazepine Hypnotics Sales by Region: 2026-2031
5.3 Global Non-benzodiazepine Hypnotics Revenue by Region: 2020-2031
5.3.1 Global Non-benzodiazepine Hypnotics Revenue by Region: 2020-2025
5.3.2 Global Non-benzodiazepine Hypnotics Revenue by Region: 2026-2031
5.4 North America Non-benzodiazepine Hypnotics Market Facts & Figures by Country
5.4.1 North America Non-benzodiazepine Hypnotics Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Non-benzodiazepine Hypnotics Sales by Country (2020-2031)
5.4.3 North America Non-benzodiazepine Hypnotics Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Non-benzodiazepine Hypnotics Market Facts & Figures by Country
5.5.1 Europe Non-benzodiazepine Hypnotics Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Non-benzodiazepine Hypnotics Sales by Country (2020-2031)
5.5.3 Europe Non-benzodiazepine Hypnotics Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Non-benzodiazepine Hypnotics Market Facts & Figures by Country
5.6.1 Asia Pacific Non-benzodiazepine Hypnotics Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Non-benzodiazepine Hypnotics Sales by Country (2020-2031)
5.6.3 Asia Pacific Non-benzodiazepine Hypnotics Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Non-benzodiazepine Hypnotics Market Facts & Figures by Country
5.7.1 South America Non-benzodiazepine Hypnotics Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Non-benzodiazepine Hypnotics Sales by Country (2020-2031)
5.7.3 South America Non-benzodiazepine Hypnotics Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Non-benzodiazepine Hypnotics Market Facts & Figures by Country
5.8.1 Middle East and Africa Non-benzodiazepine Hypnotics Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Non-benzodiazepine Hypnotics Sales by Country (2020-2031)
5.8.3 Middle East and Africa Non-benzodiazepine Hypnotics Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Non-benzodiazepine Hypnotics Sales by Type (2020-2031)
6.1.1 Global Non-benzodiazepine Hypnotics Sales by Type (2020-2031) & (K Units)
6.1.2 Global Non-benzodiazepine Hypnotics Sales Market Share by Type (2020-2031)
6.2 Global Non-benzodiazepine Hypnotics Revenue by Type (2020-2031)
6.2.1 Global Non-benzodiazepine Hypnotics Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Non-benzodiazepine Hypnotics Revenue Market Share by Type (2020-2031)
6.3 Global Non-benzodiazepine Hypnotics Price by Type (2020-2031)
7 Segment by Application
7.1 Global Non-benzodiazepine Hypnotics Sales by Application (2020-2031)
7.1.1 Global Non-benzodiazepine Hypnotics Sales by Application (2020-2031) & (K Units)
7.1.2 Global Non-benzodiazepine Hypnotics Sales Market Share by Application (2020-2031)
7.2 Global Non-benzodiazepine Hypnotics Revenue by Application (2020-2031)
7.2.1 Global Non-benzodiazepine Hypnotics Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Non-benzodiazepine Hypnotics Revenue Market Share by Application (2020-2031)
7.3 Global Non-benzodiazepine Hypnotics Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Non-benzodiazepine Hypnotics Value Chain Analysis
8.1.1 Non-benzodiazepine Hypnotics Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Non-benzodiazepine Hypnotics Production Mode & Process
8.2 Non-benzodiazepine Hypnotics Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Non-benzodiazepine Hypnotics Distributors
8.2.3 Non-benzodiazepine Hypnotics Customers
9 Global Non-benzodiazepine Hypnotics Analyzing Market Dynamics
9.1 Non-benzodiazepine Hypnotics Industry Trends
9.2 Non-benzodiazepine Hypnotics Industry Drivers
9.3 Non-benzodiazepine Hypnotics Industry Opportunities and Challenges
9.4 Non-benzodiazepine Hypnotics Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.